Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
17.04.25
/
50%
€6.75
Target price
17.04.26
€12.32
Performance (%)
-37.54%
End price
18.04.26
€4.22
Summary
This prediction ended on 18.04.26 with a price of €4.22. The BUY prediction by The_Goldman_Sachs_Gr for Myriad Genetics performed very badly with a performance of -37.54%. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | -14.556% | -14.556% | -4.611% |
| iShares Core DAX® | 0,22 % | 1,49 % | 3,58 % |
| iShares Nasdaq 100 | 6,05 % | 16,19 % | 39,14 % |
| iShares Nikkei 225® | 5,72 % | 11,69 % | 50,96 % |
| iShares S&P 500 | 2,17 % | 8,06 % | 25,62 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
In the thread Trading Myriad Genetics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten

